Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial ...
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...